Cargando…

Clinical pharmacology of alemtuzumab, an anti‐CD52 immunomodulator, in multiple sclerosis

Alemtuzumab, a humanized anti‐CD52 monoclonal antibody, is approved for treatment of relapsing multiple sclerosis (MS). In the Phase II/III trials, patients received 12 or 24 mg/day of alemtuzumab in two treatment courses (5 days for course 1 and 3 days for course 2), 12 months apart. Serum concentr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Z., Richards, S., Surks, H. K., Jacobs, A., Panzara, M. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231011/ https://www.ncbi.nlm.nih.gov/pubmed/30144037 http://dx.doi.org/10.1111/cei.13208

Ejemplares similares

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Alemtuzumab in the treatment of multiple sclerosis
por: Fernandez, Óscar
Publicado: (2014)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells
por: Lim, Che K, et al.
Publicado: (2008)

CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment
por: Hotta, Ryuichi, et al.
Publicado: (2016)

CD52-targeted depletion by Alemtuzumab ameliorates allergic airway hyperreactivity and lung inflammation
por: Shafiei-Jahani, Pedram, et al.
Publicado: (2021)

Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era
por: Kasarello, Kaja, et al.
Publicado: (2021)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
por: Havrdova, Eva, et al.
Publicado: (2017)

Role of Monoclonal Antibody "Alemtuzumab" in the Treatment of Multiple Sclerosis
por: Nosher, Sadia, et al.
Publicado: (2021)

Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52(+) T-cell malignancies
por: Miljkovic, Milos D., et al.
Publicado: (2022)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
por: Dubey, Divyanshu, et al.
Publicado: (2015)

Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis
por: Alamo, Angela, et al.
Publicado: (2019)

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts
por: Berger, Thomas, et al.
Publicado: (2016)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
por: Babij, Rachel, et al.
Publicado: (2015)

Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations
por: Dörr, Jan, et al.
Publicado: (2016)

The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis
por: Rolla, Simona, et al.
Publicado: (2020)

Thyroid Autoimmunity Following Alemtuzumab Treatment in Multiple Sclerosis Patients
por: Kazakou, Paraskevi, et al.
Publicado: (2021)

Depletion of CD52‐positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune‐tolerance promoting CD8 T‐cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis
por: von Kutzleben, Stephanie, et al.
Publicado: (2017)

Short-term outcomes of pediatric multiple sclerosis patients treated with alemtuzumab at a Canadian University multiple sclerosis clinic
por: Jure Hunt, David, et al.
Publicado: (2020)

Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis
por: Bar-Or, Amit, et al.
Publicado: (2021)

Alemtuzumab improves contrast sensitivity in patients with relapsing–remitting multiple sclerosis
por: Graves, Jennifer, et al.
Publicado: (2013)

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis
por: Akgün, Katja, et al.
Publicado: (2018)

Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients
por: Wang, Li, et al.
Publicado: (2018)

A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis
por: Aouad, Patrick, et al.
Publicado: (2018)

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
por: Holmøy, Trygve, et al.
Publicado: (2019)

Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis
por: Brannigan, Jamie, et al.
Publicado: (2020)

The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
por: Alroughani, Raed, et al.
Publicado: (2020)

COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab
por: Fernández-Díaz, Eva, et al.
Publicado: (2020)

Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis
por: Margoni, Monica, et al.
Publicado: (2019)

Refractory chronic spontaneous urticaria after the use of alemtuzumab in multiple sclerosis
por: Hu, Hannah, et al.
Publicado: (2020)

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
por: Keller, Christian W., et al.
Publicado: (2019)

Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients
por: Rauma, Ilkka, et al.
Publicado: (2021)

The budgetary impact of alemtuzumab in multiple sclerosis in Quito, Ecuador. Payer’s perspective
por: Pastor-Quirós, Luis J., et al.
Publicado: (2021)

ODP482 Graves Orbitopathy Secondary to Alemtuzumab Infusion for Multiple Sclerosis
por: Alam, Mustafa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k54q9100d2f1fpuo352d8psdpf